Comparative Pharmacology
Head-to-head clinical analysis: KETOROLAC TROMETHAMINE versus MEPRO ASPIRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETOROLAC TROMETHAMINE versus MEPRO ASPIRIN.
KETOROLAC TROMETHAMINE vs MEPRO-ASPIRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing pain and inflammation.
Meprobamate enhances GABAergic inhibition by binding to GABA-A receptors, increasing chloride conductance, while aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.
10 mg orally every 4-6 hours, not to exceed 40 mg per day; or 15-30 mg intramuscularly or intravenously every 6 hours, not to exceed 120 mg per day (maximum 60 mg for single dose).
Oral: 1-2 tablets (each containing 200 mg meprobamate and 325 mg aspirin) every 6 hours as needed; maximum 6 tablets per day.
None Documented
None Documented
Terminal half-life is 5-6 hours in young adults, prolonged to 9-10 hours in elderly patients (≥65 years) and up to 12-15 hours in renal impairment (CrCl <30 mL/min). Context: q6h dosing interval recommended; accumulation risk in elderly/renal impairment.
Aspirin: 15–20 minutes (rapid hydrolysis to salicylic acid). Salicylic acid: 2–3 hours at low doses (300–600 mg), 15–30 hours at high anti-inflammatory doses (1–2 g) due to saturable metabolism. Clinically, dosing interval is adjusted based on salicylate half-life.
Primarily renal excretion: ~92% of dose excreted in urine as parent drug (60%) and metabolites (p-hydroxyketorolac, conjugated forms). Fecal excretion accounts for ~6%. Biliary excretion is minimal.
Renal (primarily as salicyluric acid, salicyl glucuronides, and free salicylic acid). At therapeutic doses, about 10% is excreted as free salicylic acid; at toxic doses, this increases to >50%. Biliary/fecal elimination is minimal (<5%).
Category D/X
Category D/X
NSAID
NSAID / Antiplatelet